BRPI0715989A8 - "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição" - Google Patents

"seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição"

Info

Publication number
BRPI0715989A8
BRPI0715989A8 BRPI0715989A BRPI0715989A BRPI0715989A8 BR PI0715989 A8 BRPI0715989 A8 BR PI0715989A8 BR PI0715989 A BRPI0715989 A BR PI0715989A BR PI0715989 A BRPI0715989 A BR PI0715989A BR PI0715989 A8 BRPI0715989 A8 BR PI0715989A8
Authority
BR
Brazil
Prior art keywords
antibody
antibodies
composition
sequences
chain
Prior art date
Application number
BRPI0715989A
Other languages
English (en)
Portuguese (pt)
Inventor
Stephen Zhou Bin-Bing
Li Kang
Singh Sanjaya
Chung Fung Sek
Wu Wenjuan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0715989A2 publication Critical patent/BRPI0715989A2/pt
Publication of BRPI0715989A8 publication Critical patent/BRPI0715989A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
BRPI0715989A 2006-10-19 2007-10-18 "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição" BRPI0715989A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85286106P 2006-10-19 2006-10-19
US87921807P 2007-01-06 2007-01-06
PCT/US2007/081797 WO2008051797A2 (en) 2006-10-19 2007-10-18 Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases

Publications (2)

Publication Number Publication Date
BRPI0715989A2 BRPI0715989A2 (pt) 2014-03-18
BRPI0715989A8 true BRPI0715989A8 (pt) 2018-03-13

Family

ID=39325263

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715989A BRPI0715989A8 (pt) 2006-10-19 2007-10-18 "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição"

Country Status (19)

Country Link
US (5) US7994285B2 (OSRAM)
EP (1) EP2087006B1 (OSRAM)
JP (1) JP5478254B2 (OSRAM)
KR (2) KR20150023953A (OSRAM)
AR (1) AR063494A1 (OSRAM)
AU (1) AU2007309229B8 (OSRAM)
BR (1) BRPI0715989A8 (OSRAM)
CA (1) CA2666672A1 (OSRAM)
CL (1) CL2007002987A1 (OSRAM)
CO (1) CO6180445A2 (OSRAM)
CR (1) CR10730A (OSRAM)
MA (1) MA30900B1 (OSRAM)
MX (1) MX2009004106A (OSRAM)
NO (1) NO20091926L (OSRAM)
PE (1) PE20081264A1 (OSRAM)
PH (1) PH12015500576A1 (OSRAM)
RU (1) RU2461569C2 (OSRAM)
TW (1) TW200824707A (OSRAM)
WO (1) WO2008051797A2 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
WO2008057144A2 (en) * 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CA2666179A1 (en) 2006-10-19 2008-11-13 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
CA2666672A1 (en) * 2006-10-19 2008-05-02 Genentech, Inc. Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
TWI419904B (zh) * 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
AU2008209482B2 (en) 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
BRPI0815291A2 (pt) * 2007-08-23 2015-02-03 Univ Columbia "proteina de fusão, metodo de tratamento de pacientes que possuem um tumor, método de inibição da angiogênese em pacientes, método de tratamento de pacientes que possuem câncer do ovário, método de tratamento de pacientes que possuem um distúrbio metábolico, uso de proteína de fusão, método de inibição de linfoangiogênese patológica em pacientes, método de inibição da metástase de tumores em pacientes, método de inibição do crescimento de tumores secundários em pacientes, métodos de inibição da cooptação de vasos sanguineos por um tumor em pacientes, método de tratamento de cancer em pacientes e método de tratamento da retinopatia proliferativa vascular"
NZ590127A (en) * 2008-07-08 2012-11-30 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CA2733902A1 (en) 2008-08-22 2010-02-25 The Trustees Of Columbia University In The City Of New York Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
PE20120080A1 (es) * 2008-10-01 2012-02-17 Genentech Inc Anticuerpos anti-notch2 y metodos de uso
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
JP5113812B2 (ja) * 2009-08-31 2013-01-09 清 中川 コロニーピッキング装置、コロニーピッキング方法、及び融合細胞クローン作製方法
RU2012117619A (ru) 2009-09-30 2013-11-10 Дженентек, Инк. ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3
US20130095493A1 (en) * 2011-10-03 2013-04-18 The Johns Hopkins University Identification of the gene notch3 as a novel biomarker for human metastatic melanoma
TW201329105A (zh) 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物
WO2013167620A1 (en) * 2012-05-10 2013-11-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Immunomodulatory methods using notch agonists
BR112015010436A2 (pt) * 2012-11-07 2017-08-22 Pfizer Anticorpos anti-notch3 e conjugados anticorpo-fármaco
PL2935330T3 (pl) * 2012-12-19 2019-11-29 Aveo Pharmaceuticals Inc Przeciwciała przeciw notch3
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
US9683039B2 (en) * 2013-03-14 2017-06-20 New York University Notch agonists for the treatment of cancer
CN106459919B (zh) * 2014-06-04 2021-03-23 弗莱德哈钦森癌症研究中心 使用notch 1和/或notch 2激动剂扩增和植入干细胞
MX2017000363A (es) 2014-07-11 2017-04-27 Genentech Inc Inhibicion de la via de notch.
EP3197494A1 (en) * 2014-09-25 2017-08-02 Inserm Immunological treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
TWI897070B (zh) * 2016-03-31 2025-09-11 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
EP3448420B1 (en) * 2016-04-29 2022-09-14 Aveo Pharmaceuticals, Inc. Anti-notch3 antibody
WO2018183216A1 (en) 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Notch3 agonist compositions and methods for treating small vessel diseases
WO2018183213A1 (en) * 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Blood biomarkers and diagnostic methods for small vessel diseases
WO2019041024A1 (en) * 2017-08-29 2019-03-07 Gary Levy FGL2 ANTIBODIES AND BINDING FRAGMENTS THEREOF AND USES THEREOF
CN112930393A (zh) 2018-08-28 2021-06-08 福瑞德哈金森癌症研究中心 结合诱导的Notch信号传导的过继T细胞疗法的方法和组合物
JP6892180B2 (ja) * 2018-12-03 2021-06-23 株式会社ｍＡｂＰｒｏｔｅｉｎ 活性型インターロイキン−１８タンパク質のネオエピトープを認識する抗体、及びその応用
US20230383011A1 (en) * 2020-06-30 2023-11-30 Chugai Seiyaku Kabushiki Kaisha Site specific notch-activating molecule and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
JPH09506262A (ja) * 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US20050158859A1 (en) * 1995-09-29 2005-07-21 Yale University Manipulation of non-terminally differentiated cells using the Notch pathway
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
US6692919B1 (en) * 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US6436650B1 (en) * 1997-07-23 2002-08-20 Yale University Activated forms of notch and methods based thereon
FR2777285B1 (fr) 1998-04-10 2000-05-19 Bio Merieux Ligand peptidique presentant une affinite specifique vis-a-vis de la proteine p24 du retrovirus hiv-1
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
AU2001288628A1 (en) * 2000-08-31 2002-03-13 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
DK1318830T3 (da) 2000-09-22 2013-01-28 Genentech Inc Konstitutivt aktiv form af Notch1-receptor eller et anti-Notch1-receptor til behandling af prostatacancer
WO2004013179A1 (en) * 2002-08-03 2004-02-12 Lorantis Limited Conjugate of notch signalling pathway modulators and their use in medical treatment
US7837993B2 (en) 2004-03-19 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for regeneration of aged skeletal muscle tissues
CA2573293A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
WO2006068822A1 (en) 2004-12-20 2006-06-29 Genentech, Inc. Notch receptor agonists and uses
WO2007070671A2 (en) * 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
CA2666179A1 (en) 2006-10-19 2008-11-13 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
CA2666672A1 (en) * 2006-10-19 2008-05-02 Genentech, Inc. Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
TWI419904B (zh) * 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica

Also Published As

Publication number Publication date
US7915390B2 (en) 2011-03-29
PE20081264A1 (es) 2008-10-01
CR10730A (es) 2009-06-19
CL2007002987A1 (es) 2008-06-06
US20080131908A1 (en) 2008-06-05
MA30900B1 (fr) 2009-11-02
US7994285B2 (en) 2011-08-09
US8187839B2 (en) 2012-05-29
AU2007309229A2 (en) 2009-05-28
RU2009118621A (ru) 2010-11-27
CA2666672A1 (en) 2008-05-02
AU2007309229B8 (en) 2013-05-09
CO6180445A2 (es) 2010-07-19
WO2008051797A3 (en) 2008-07-31
JP2010506596A (ja) 2010-03-04
PH12015500576A1 (en) 2016-07-25
AR063494A1 (es) 2009-01-28
AU2007309229A1 (en) 2008-05-02
US9518124B2 (en) 2016-12-13
WO2008051797A2 (en) 2008-05-02
KR20090080979A (ko) 2009-07-27
JP5478254B2 (ja) 2014-04-23
KR20150023953A (ko) 2015-03-05
US20140093889A1 (en) 2014-04-03
MX2009004106A (es) 2009-04-28
EP2087006B1 (en) 2016-06-08
KR101525629B1 (ko) 2015-06-26
AU2007309229B2 (en) 2013-01-10
TW200824707A (en) 2008-06-16
RU2461569C2 (ru) 2012-09-20
US20110206675A1 (en) 2011-08-25
US20120213785A1 (en) 2012-08-23
EP2087006A2 (en) 2009-08-12
NO20091926L (no) 2009-07-17
BRPI0715989A2 (pt) 2014-03-18
US20100111971A9 (en) 2010-05-06
US20080118520A1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
BRPI0715989A8 (pt) "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição"
NO2020036I1 (no) Isolert antistoff eller fragment derav omfattende lett kjede og tung kjede CDR-sekvenser ifølge NO344867 krav 1 (SEQ ID NO: 224, 225, 226 og 146, 147, 148), der antistoffet eller fragmentet derav binder human IL-17 reseptor A; spesielt et antistoff omfattende lett kjede og tung kjede variable domenesekvenser ifølge NO344867 krav 2 (SEQ ID NO: 40 and 14); slik som et IgG2 antistoff omfattende lett og tung kjede variable domenesekvenser ifølge NO344867 krav 4 (SEQ ID NO: 40 and 14); og spesielt brodalumab; og dets derivater dekket av NO344867.
BRPI0905076A2 (pt) Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo
BRPI0812878B8 (pt) anticorpo isolado ou parte funcional do mesmo, vetor, método para produzir um anticorpo ou uma parte funcional do mesmo, para produzir uma célula produtora de anticorpo e para produzir um anticorpo capaz de se ligar especificamente a rsv, composição, e, uso de um anticorpo ou parte funcional do mesmo ou de uma composição ou de vetor
BRPI0917592A2 (pt) "polipeptídeo de região variável de cadeia pesada, anticorpos anti-pd-l1, fragmentos de ligação ao antígeno, composições, ácidos nucleicos, vetor, célula hospedeira, processo para produção de anticorpo anti-pd-l1, artigos de fabricação, método de acentuação da função da célula t, método de tratamento de um distúrbio disfuncional de célula t e uso de uma composição"
BRPI0819211A2 (pt) Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
BRPI0811382A2 (pt) "anticorpos anti-notch1 nrr isolados, polinucleotídeo, vetor, célula hospedeira, método para produzir um anticorpo anti-notch1 nrr, uso do anticorpo anti-notch1 nrr e composição"
WO2008022295A3 (en) Prlr-specific antibody and uses thereof
DK1752471T3 (da) Syntetiske immunoglogulindomæner med bindende egenskaber, der er modificerede i områder af molekylet, og som adskiller sig fra de komplementaritetsbestemmende områder
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
BRPI0812400A2 (pt) Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
BRPI0821447A2 (pt) Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
WO2010115589A8 (en) Trivalent, bispecific antibodies
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
CR10273A (es) "anticuerpos anti-5t4 y usos de los mismos"
NZ597447A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
EP2796466A3 (en) Humanized antibody molecules specific for IL-31
WO2011064257A3 (de) Monospezifische polypeptidreagenzien
GEP20115226B (en) P-cadherin antibodies
WO2008098917A3 (en) Novel antibodies against igf-ir

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2536 DE 13-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.